Proactive news headlines including Paradigm Biopharmaceuticals, Andromeda Metals, Frontier Energy and Imugene Ltd – Press Release

[ad_1]

Sydney, Aug. 08, 2022 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:

• Paradigm Biopharmaceuticals Ltd (ASX:PAR) is poised to present data from its open-label Phase 2 study on pentosan polysulfate sodium (PPS) at the 2023 International Conference on Lysosomal Diseases (ICLD) meeting. Click here
• Andromeda Metals Ltd (ASX:ADN) has a second binding offtake agreement under its belt to supply its Great White KCM™90 product from the Great White Kaolin Project in South Australia to Japanese porcelain manufacturer Plantan Yamada Co Ltd. Click here
• Frontier Energy Ltd (ASX:FHE) has appointed Amanda Reid as non-executive director. Click here
• Imugene Ltd ((ASX:IMU, OTC:IUGNF) has presented findings from its PD1-Vaxx trial in non-small cell lung cancer patients at the International Association for the Study of Lung Cancer's annual conference. Click here
• Creso Pharma Ltd ((ASX:CPH, OTCQB:COPHF) wholly owned Canadian subsidiary, Mernova Medicinal Inc. has continued to deliver strong results in relation to the uptake of its Ritual brands. Click here
• Rumble Resources Ltd (ASX:RTR)'s earn-in partner, AIC Mines Ltd, has updated the …

Full story available on Benzinga.com

[ad_2]

Source link